From Androgen Deprivation to Precision Therapy: A Bibliometric Review of Global Research Trends (2008–2023)

This review employs bibliometric methods to map the evolving landscape of prostate cancer endocrine therapy research over the past 15 years. Through analysis of 961 articles from the Web of Science Core Collection, we identified key trends in therapeutic innovation and clinical translation. The Unit...

Full description

Saved in:
Bibliographic Details
Main Authors: Longjun Huang, Wenjuan He, Yong Guo
Format: Article
Language:English
Published: SAGE Publishing 2025-06-01
Series:American Journal of Men's Health
Online Access:https://doi.org/10.1177/15579883251346819
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850208822703947776
author Longjun Huang
Wenjuan He
Yong Guo
author_facet Longjun Huang
Wenjuan He
Yong Guo
author_sort Longjun Huang
collection DOAJ
description This review employs bibliometric methods to map the evolving landscape of prostate cancer endocrine therapy research over the past 15 years. Through analysis of 961 articles from the Web of Science Core Collection, we identified key trends in therapeutic innovation and clinical translation. The United States emerged as the dominant contributor (34.96% of publications), with Harvard University and the University of California System leading institutional output. Three paradigm shifts emerged: early stage research focused on optimizing androgen deprivation therapy (ADT) efficacy (2008–2013), followed by castration-resistant prostate cancer (CRPC) drug development (2014–2016), and recent emphasis on combination therapies and molecular targeting (2017–2023). The top 50 most cited papers confirmed that keyword clusters directly corresponded to pivotal trials, including TAMPEDE (NCT00268476) and PROSPER (NCT02003924). The translational science spectrum model revealed that 68% of current clinical applications originated from basic research on androgen receptor variants. Emerging frontiers include prostate-specific membrane antigen-targeted radioligand therapy and immunotherapy-ADT synergies. This synthesis provides clinicians with an evidence-based roadmap to navigate therapeutic advancements while highlighting the critical need for international collaboration in addressing persistent challenges such as treatment resistance.
format Article
id doaj-art-5773bfbe39734ad1bb63f46cb97f5afb
institution OA Journals
issn 1557-9891
language English
publishDate 2025-06-01
publisher SAGE Publishing
record_format Article
series American Journal of Men's Health
spelling doaj-art-5773bfbe39734ad1bb63f46cb97f5afb2025-08-20T02:10:09ZengSAGE PublishingAmerican Journal of Men's Health1557-98912025-06-011910.1177/15579883251346819From Androgen Deprivation to Precision Therapy: A Bibliometric Review of Global Research Trends (2008–2023)Longjun Huang0Wenjuan He1Yong Guo2The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, ChinaThe First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, ChinaDepartment of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, ChinaThis review employs bibliometric methods to map the evolving landscape of prostate cancer endocrine therapy research over the past 15 years. Through analysis of 961 articles from the Web of Science Core Collection, we identified key trends in therapeutic innovation and clinical translation. The United States emerged as the dominant contributor (34.96% of publications), with Harvard University and the University of California System leading institutional output. Three paradigm shifts emerged: early stage research focused on optimizing androgen deprivation therapy (ADT) efficacy (2008–2013), followed by castration-resistant prostate cancer (CRPC) drug development (2014–2016), and recent emphasis on combination therapies and molecular targeting (2017–2023). The top 50 most cited papers confirmed that keyword clusters directly corresponded to pivotal trials, including TAMPEDE (NCT00268476) and PROSPER (NCT02003924). The translational science spectrum model revealed that 68% of current clinical applications originated from basic research on androgen receptor variants. Emerging frontiers include prostate-specific membrane antigen-targeted radioligand therapy and immunotherapy-ADT synergies. This synthesis provides clinicians with an evidence-based roadmap to navigate therapeutic advancements while highlighting the critical need for international collaboration in addressing persistent challenges such as treatment resistance.https://doi.org/10.1177/15579883251346819
spellingShingle Longjun Huang
Wenjuan He
Yong Guo
From Androgen Deprivation to Precision Therapy: A Bibliometric Review of Global Research Trends (2008–2023)
American Journal of Men's Health
title From Androgen Deprivation to Precision Therapy: A Bibliometric Review of Global Research Trends (2008–2023)
title_full From Androgen Deprivation to Precision Therapy: A Bibliometric Review of Global Research Trends (2008–2023)
title_fullStr From Androgen Deprivation to Precision Therapy: A Bibliometric Review of Global Research Trends (2008–2023)
title_full_unstemmed From Androgen Deprivation to Precision Therapy: A Bibliometric Review of Global Research Trends (2008–2023)
title_short From Androgen Deprivation to Precision Therapy: A Bibliometric Review of Global Research Trends (2008–2023)
title_sort from androgen deprivation to precision therapy a bibliometric review of global research trends 2008 2023
url https://doi.org/10.1177/15579883251346819
work_keys_str_mv AT longjunhuang fromandrogendeprivationtoprecisiontherapyabibliometricreviewofglobalresearchtrends20082023
AT wenjuanhe fromandrogendeprivationtoprecisiontherapyabibliometricreviewofglobalresearchtrends20082023
AT yongguo fromandrogendeprivationtoprecisiontherapyabibliometricreviewofglobalresearchtrends20082023